EDANS (1,5-EDANS) is a novel quenched fluorogenic substrate for the analysis of retroviral proteases through resonance energy transfer.

Physicochemical Properties

Molecular Formula	C12H14N2O3S
Molecular Weight	266.32
Exact Mass	266.073
CAS #	50402-56-7
Related CAS #	EDANS sodium;100900-07-0
PubChem CID	92329
Appearance	White to off-white solid powder
Density	1.432 g/cm3
Melting Point	>350°C
Index of Refraction	1.691
LogP	3.311
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	4
Heavy Atom Count	18
Complexity	366
Defined Atom Stereocenter Count	0
InChi Key	SJQRQOKXQKVJGJ-UHFFFAOYSA-N
InChi Code	InChI=1S/C12H14N2O3S/c13-7-8-14-11-5-1-4-10-9(11)3-2-6-12(10)18(15,16)17/h1-6,14H,7-8,13H2,(H,15,16,17)
Chemical Name	5-(2-aminoethylamino)naphthalene-1-sulfonic acid
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage.(2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	The natural processing site of HIV-1 PR is the source of the peptide sequence of EDANS[1]. When fluorescent substrates are added to recombinant HIV-1 PR, the Tyr-Pro bond is specifically broken and the intensity of the fluorescence increases with time in a manner that is directly proportional to the degree of substrate hydrolysis [1].
References	[1]. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science. 1990 Feb 23;247(4945):954-8.

Solubility Data

Solubility (In Vitro)

DMSO: 13.89 mg/mL (52.16 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 1.39 mg/mL (5.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 13.9 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.39 mg/mL (5.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 13.9 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.39 mg/mL (5.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 13.9 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.7549 mL	18.7744 mL	37.5488 mL
	5 mM	0.7510 mL	3.7549 mL	7.5098 mL
	10 mM	0.3755 mL	1.8774 mL	3.7549 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.